logo

For the Inventor, By the Inventor

Stockholm, Sweden

Biovitrum Ab

Calculating rank
USPTO Granted Patents = 55

% Expired Patents = 70.9



Forward Citations = 507

Loading Chart...
Loading Chart...

108 inventors (with patents filed for the assignee):

goldMedal Gary Johansson (9 out of 14 patents)

silverMedal Patrizia Caldirola (9 out of 11 patents)

bronzeMedal Jerk Vallgårda (9 out of 10 patents)

4.  Björn M Nilsson (8 out of 15 patents)

5.  Jan Tejbrant (8 out of 8 patents)

6.  Marianne Nilsson (8 out of 11 patents)

7.  Ulf J Bremberg (7 out of 14 patents)

8.  Annika Jenmalm Jensen (7 out of 8 patents)

9.  Andrew Mott (7 out of 7 patents)

10.  Guido Kurz (6 out of 7 patents)

11.  Lori Sutin (6 out of 7 patents)

12.  Markus Thor (6 out of 6 patents)

13.  Erik Ringberg (5 out of 17 patents)

14.  Meredith Williams (5 out of 10 patents)

15.  Tjeerd Barf (5 out of 7 patents)


Core Competencies:
Inhibitors
11-Beta-Hydroxysteroid Dehydrogenase
Obesity Treatments
Cyclolignans
Sulfonamide Compounds
Amino-Substituted Pyrazines
Pharmaceutical Formulations
Receptor Structures
Drug Design
Bacterial Structures
Biocompatible Polymers
Serotonin-Related Diseases

55 patents:

1. 8686011 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2014-04-01),
2. 8541592 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (2013-09-24),
3. 7820675 - Benzofuran compounds (2010-10-26),
4. 7718650 - Aryl sulfonamide compounds for treating obesity (2010-05-18),
5. 7709526 - Use of cyclolignans and new cyclolignans (2010-05-04),
6. 7671051 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2010-03-02),
7. 7666888 - Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 (2010-02-23),
8. 7618961 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 (2009-11-17),
9. 7572787 - Substituted naphthalene sulfonamides (2009-08-11),
10. 7566715 - Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system (2009-07-28),
11. 7534794 - Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases (2009-05-19),
12. 7319097 - Compounds (2008-01-15),
13. 7285392 - Methods for identifying active compounds (2007-10-23),
14. 7253196 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2007-08-07),
15. 7247633 - Pyrimidine compounds and their use (2007-07-24),
Company Overview
Biovitrum AB, based in Stockholm, Sweden, specializes in the development and manufacturing of pharmaceutical compounds with a focus on innovative treatments for obesity and related metabolic disorders. The company is recognized for its expertise in various core technology topics, including inhibitors targeting 11-beta-hydroxysteroid dehydrogenase, as well as the development of cyclolignans and sulfonamide compounds. Biovitrum's research emphasizes advanced pharmaceutical formulations and receptor structures, positioning it as a key player in the pharmaceutical industry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

55 Patents

#18 in Stockholm

#127 in Sweden

#12,945 in the World

Stockholm, SE
Stockholm, Sweden

Biovitrum Ab

Forward Citations = 507

108 inventors:

goldMedal Gary Johansson (9 out of 14 patents)

silverMedal Patrizia Caldirola (9 out of 11 patents)

bronzeMedal Jerk Vallgårda (9 out of 10 patents)

4.  Björn M Nilsson (8 out of 15 patents)

5.  Jan Tejbrant (8 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biovitrum Ab. Retrieved from https://idiyas.com/company/biovitrum-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…